test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works

Advanced Search
& Collections
Issue Date   
Sign on to:   
Receive email
My Account
authorized users
Edit Profile   
About T-Space   

T-Space at The University of Toronto Libraries >
School of Graduate Studies - Theses >
Master >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/17701

Title: A Cost-effectiveness Analysis of Capecitabine and Folfox for the Adjuvant Treatement of Stage III Colon Cancer: Which is the More Cost-Effective Option in Ontario?
Authors: Orchard, Margo
Advisor: Hoch, Jeffrey
Barnsley, Janet
Department: Health Policy, Management and Evaluation
Keywords: economic evaluation
Issue Date: 22-Sep-2009
Abstract: Background: There are a number of treatment options for colon cancer. These regimens have different toxicity profiles and the age of the patient may affect outcomes of care and cost-effectiveness. An economic evaluation was conducted to explore treatment options for stage III colon cancer. Methods: A Markov model was developed to compare the cost-effectiveness of capecitabine with oxaliplatin combined with fluorouracil/leucovorin (FOLFOX) for the adjuvant treatment of stage III colon cancer. Results: At age 70, FOLFOX was the preferred option, costing $25,314 per quality-adjusted life-year gained. However, the difference in effect between the regimens ranged by 6 months and the model was sensitive to a number of variables. At age 80, capecitabine became the preferred option. Conclusion: FOLFOX is the most cost-effective treatment option in Ontario, but above age 80, capecitabine becomes the favoured option. Uncertainty remains in determining the most cost-effective treatment option for stage III colon cancer.
URI: http://hdl.handle.net/1807/17701
Appears in Collections:Master
The Institute of Health Policy, Management and Evaluation - Master theses

Files in This Item:

File Description SizeFormat
Orchard_Margo_C_20096_MSc_thesis.pdf459.12 kBAdobe PDF

This item is licensed under a Creative Commons License
Creative Commons

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.